Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 87

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 87
---
 distribution and sale of non-opioid pain management and regenerative health solutions. The Company is managed by a single management team, and, consistent with its organizational structure, the Chief Executive Officer—who is the Company’s chief operating decision maker, or CODM—manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one operating segment and one reportable segment to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.The key measure of the Company is GAAP net income. The CODM uses this measure to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.There are significant expense categories and amounts that are regularly provided to the CODM. These expense categories differ from what is disclosed in the Company’s financial results. The table below reconciles the significant expense categories provided to the CODM to the Company’s expenses as disclosed under U.S. GAAP (in thousands):

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-47

Table of ContentsPACIRA BIOSCIENCES, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Year Ended December 31,202420232022Revenues$700,966 $674,978 $666,823 Less:Adjusted cost of goods sold165,097 173,980 174,856 Adjusted research and development74,196 67,563 78,203 Adjusted selling and marketing172,015 153,040 144,996 Adjusted general and administrative86,385 82,737 73,989 Goodwill impairment163,243 — — Stock-based compensation51,171 47,895 48,092 Amortization of acquired intangible assets57,288 57,288 57,288 Changes in the fair value of contingent consideration(4,457)(3,424)(29,476)Impairment of acquired IPR&D— — 26,134 Accelerated depreciation— — 10,545 Other (1)9,399 8,224 22,172 Total operating expenses774,337 587,303 606,799 Adjusted other income (expense)2,747 (9,048)(46,722)Gain (loss) on early extinguishment of debt7,518 (16,926)— Total other income (